TYRA’s dabogratinib advances to phase III for intermediate-risk NMIBC
Dabogratinib, an oral therapy for intermediate-risk NMIBC, posted 64% CR and 100% ORR in single marker lesions in phase II. Company says robust efficacy and safety support phase III advancement.
Dabogratinib showed strong phase II efficacy and safety as an oral therapy for intermediate-risk NMIBC, with a 64% CR rate and 100% ORR in single marker lesions, positioning it as a leading candidate for phase III trials. The drug’s favorable safety profile and oral dosing address major unmet needs in this setting.